REVVITY, INC（RVTY）の決算・業績分析
REVVITY, INCの2025年有価証券報告書をAI分析。売上高$2.9B(+3.7%)。営業利益$357M。Health Care。
目次
REVVITY, INCの2025年度 業績サマリー
REVVITY, INC（証券コード: RVTY）の2025年度決算・業績分析。売上高は$2.9B（前年比+3.7%）。営業利益は$357M（前年比+2.9%）。純利益は$241M（前年比-10.8%）。有価証券報告書を基に、業績変化の要因・リスク・見通し・セグメント構成を AI が分析しました。
REVVITY, INCの2024年度 注目ポイント
※ 直近の2025年度XBRLデータは取込済みですが、AI分析は2024年度の10-Kを対象としています。
- Revenue declined 13.5% YoY to $3.3B (XBRL), driven by a 3% drop in Life Sciences segment revenue (10-K).
- Operating income fell 41.0% YoY to $743M (XBRL), despite a 166 bps improvement in operating margin to 22.4% (10-K).
- Net debt rose to $2.7B (2.3x EBITDA) (XBRL), reflecting a $3.2B long-term debt balance (XBRL).
- Shareholder returns totaled $116M via dividends ($35M) and buybacks ($81M) (XBRL).
REVVITY, INCの売上高変化の要因
- •Total revenue declined 13.5% YoY to $3.3B (XBRL), with the Life Sciences segment falling 3% to $1,254.1M (10-K) and the Diagnostics segment rising 3% to $1,500.9M (10-K). The decline in Life Sciences was attributed to product mix shifts and market headwinds, while Diagnostics growth stemmed from demand in immunodiagnostics and reproductive health (10-K).
REVVITY, INCの営業利益変化の要因
- •Operating margin improved 166 bps YoY to 22.4% (10-K), despite a 41.0% YoY drop in operating income to $743M (XBRL). Gross margin fell 16 bps YoY to 55.8% (10-K), driven by unfavorable product mix and higher costs. Net margin declined 39.7% YoY to 17.2% (XBRL), reflecting the impact of lower revenue and higher costs. EBITDA grew 35.3% YoY to $1.2B (XBRL).
REVVITY, INCの事業リスクと対応
Economic downturns or government funding cuts could reduce demand and create collection risks (10-K).
Global geopolitical instability, trade barriers, or conflicts (e.g., Ukraine/Middle East) may disrupt operations (10-K).
Failure to innovate or introduce new products may lead to loss of market share (10-K).
Catastrophic events (e.g., natural disasters) could damage facilities and operations (10-K).
Regulatory changes or delays in approvals may hinder product commercialization (10-K).
Net debt of $2.7B (2.3x EBITDA) (XBRL) increases leverage risk.
Revenue decline of -13.5% YoY to $3.3B (XBRL) and operating income drop of -41.0% YoY to $743M (XBRL) highlight profitability pressures.
REVVITY, INCの今後の見通し・業績予想
REVVITY, INCの事業内容
Revvity, Inc. (RVTY) operates in the health science sector, providing life sciences and diagnostics solutions through products like reagents, imaging tools, and assay kits (10-K). Key customers include pharmaceutical companies, biotech firms, academic institutions, and government entities, with no significant customer concentration (10-K). The Life Sciences segment (revenue: $1,254.1M) focuses on reagents and instruments, while the Diagnostics segment (revenue: $1,500.9M) emphasizes immunodiagnostics and reproductive health (10-K). Competitive advantages and intellectual property are not explicitly detailed in the 10-K.
REVVITY, INCのAI業績分析レポート（2024年度）
Revvity, Inc. (RVTY) FY2024 Annual Report Analysis
Highlights
Business Overview
Revvity operates in the health science sector, offering life sciences and diagnostics solutions through products like reagents, imaging tools, and assay kits (10-K). Key customers include pharmaceutical companies, biotech firms, academic institutions, and government entities, with no significant customer concentration (10-K). The Life Sciences segment (revenue: $1,254.1M) focuses on reagents and instruments, while the Diagnostics segment (revenue: $1,500.9M) emphasizes immunodiagnostics and reproductive health (10-K). Competitive advantages and intellectual property are not explicitly detailed in the 10-K.
Revenue Analysis
Total revenue declined 13.5% YoY to $3.3B (XBRL), with the Life Sciences segment falling 3% to $1,254.1M (10-K) and the Diagnostics segment rising 3% to $1,500.9M (10-K). The Life Sciences decline was attributed to product mix shifts and market headwinds, while Diagnostics growth stemmed from demand in immunodiagnostics and reproductive health (10-K).
Profitability Analysis
Operating margin improved 166 bps YoY to 22.4% (10-K), despite a 41.0% YoY drop in operating income to $743M (XBRL). Gross margin fell 16 bps YoY to 55.8% (10-K), driven by unfavorable product mix and higher costs. Net margin declined 39.7% YoY to 17.2% (XBRL), reflecting the impact of lower revenue and higher costs. EBITDA grew 35.3% YoY to $1.2B (XBRL).
Balance Sheet Analysis
Equity ratio rose to 52.6% (XBRL), with total equity at $7.1B (10-K) and total assets at $13.6B (10-K). Long-term debt increased to $3.2B (XBRL), resulting in net debt of $2.7B (2.3x EBITDA) (XBRL). Current ratio remained strong at 2.07x (XBRL), and cash reserves stood at $454M (XBRL).
Cash Flow Analysis
Operating cash flow totaled $680M (XBRL), with free cash flow (FCF) of $594M (XBRL) after $86M in CapEx (XBRL). Investing cash flow was -$133M (XBRL), and financing cash flow was -$662M (XBRL), driven by $35M in dividends and $81M in share repurchases (XBRL).
Working Capital Analysis
Receivables days: 70 days; Inventory days: 47 days; Payables days: 22 days; Cash Conversion Cycle (CCC): 94 days (XBRL).
Risks
Outlook
Management expects continued market headwinds in Life Sciences, product mix shifts, and productivity initiatives to drive margin improvements (10-K). No specific forward-looking guidance is provided in the 10-K.
Historical Time Series
| Metric | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|
| Revenue | 2.8B | 2.9B | 2.7B | 3.8B | 3.3B | 2.8B |
| Operating Income | 324M | 362M | 867M | 1.3B | 743M | 301M |
| Net Income | 238M | 228M | 728M | 943M | 569M | 693M |
| Total Assets | 6.5B | 8.0B | 15.0B | 14.1B | 13.6B | 12.4B |
| Total Equity | 2.5B | 2.6B | 2.8B | 3.7B | 7.1B | 7.4B |
| Operating Cash Flow | 311M | 363M | 892M | 1.4B | 680M | 91M |
Health Careの企業一覧
REVVITY, INCと同じ「Health Care」セクターの企業